“We are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.” Locked and loaded.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.